Albany, NY (PRWEB) December 09, 2014
This report is a study of the global oncogenic or cancer biomarker market, with special emphasis on the United States regional market. The discovery, development, and opportunities of companion diagnostics and personalized medicine have also been discussed in the cancer biomarker market report. Growth forecasts and projections on a global and regional scale have been presented in this report with regard to cancer biomarker market size, volume, production, market value, industry share, and demographics.
View Full Report at http://www.marketresearchreports.biz/analysis/195508
The global biomarker market can be segmented on the basis of therapy into cardiology, arthritis, oncology, diabetes, renal disorders, infectious disease (e.g., HIV, TB), and neurology. Of these, the oncology or cancer biomarker market is the most flourishing therapeutic segment.
The report on the cancer biomarker market tracks and studies current trends, developments and technologies in the field of oncology. Personalized medicine and pharmacogenomics have gained much recognition and popularity in recent years and the report analyzes the impact that these trends have had on the cancer biomarker market.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/195508
One of the primary forces driving the cancer biomarker market is the increasing prevalence of cancer across the globe. The report studies the use and impact of cancer biomarkers in the identification, diagnosis, and correlation of the various types of cancer such as cancer of the lung, bowel, prostate, breast, and skin. Apart from this, the report also identifies and evaluates the numerous factors driving the cancer biomarker market. These include growing patient awareness and emphasis on early diagnosis, increasing healthcare professional awareness, improvement in testing capabilities, rise in awareness regarding the uptake of advanced technologies, developments in cancer biomarker research, growing investments and government initiatives, and rise in number of targeted clinical trials in the field of oncology.
Offering a plethora of information on the various current and pipeline cancer biomarkers in the market, the report also comprehensively evaluates the significant impact they have had in the field. Some of the key cancer biomarkers studied in the research report include PARP – Inhibitors, Ataxia Telangiectasia Mutated (ATM), PTEN – the Tumour Suppressor Gene, P53 Transcription Factor Oncogenic Mutations, Significant Molecular Targets of MiR – 17/92, TMPRSS2 – ERG, BRCA – Mutant Breast and Ovarian Cancer biomarkers, MiR – 17/92 Cluster, and Epidermal Growth Factor Receptor (EGFR).
Explore All Therapeutic Area Market Research Reports at http://www.marketresearchreports.biz/category/37
The report offers an in-depth analysis of the competitive landscape of the global and USA cancer biomarker market, identifying key players operating within the industry. Some of the leading participants of the cancer biomarker market profiled in the report include Atossa Genetics, Myriad, Genomic Health, Celldex Therapeutics, Genelex, Celera (Quest Diagnostics), Illumina, 23andMe, Qiagen, Astex Pharmaceuticals (Otuska Pharamceutical), BioMerieux, Affymetrix, Foundation Medicine, Nodality, and deCode Genetics (Amgen).
Marketresearchreports.biz is the most comprehensive collection of market research reports, supporting clients’ market intelligence needs with over 100,000 market research reports, company profiles, data books, and regional market profits in its repository. We also offer consulting support for custom market research needs.
Our document database is updated by the hour, which means that our customers always have access to fresh data spanning over 300 industries. From Fortune 500 companies to SMEs, Marketresearchreports.biz has built a veritable reputation for fulfilling the most exacting market research needs.
Browse Blog at https://businessmonitorinternational.wordpress.com/